골격 이형성증약 시장 : 이형성 유형, 치료, 유통 채널별 - 세계 예측

Skeletal dysplasia drugs market size is projected to witness 4.2% CAGR between 2024 and 2032 driven by the increasing prevalence and diagnosis of skeletal dysplasia. As per reports, non-lethal skeletal dysplasia occurs in approximately 1 in 26,000 to 1 in 28,000 live births, impacting around 250,000 people worldwide.

Advancements in genetic research and improved diagnostic techniques have resulted in more accurate and early identification of these rare conditions, leading to the higher demand for targeted therapies. The growing awareness and understanding among healthcare professionals and the public are also contributing to increased diagnosis rates, further driving the need for specialized treatments. Pharmaceutical companies are also investing in clinical trials and developing novel drug candidates that target the underlying genetic causes of these conditions. Government incentives, such as orphan drug designations and grants, are further supporting the development and commercialization of new therapies.

The industry is divided into dysplasia type, treatment, distribution channel, and region.

Based on treatment, the skeletal dysplasia market from the human monoclonal antibody segment is projected to observe substantial CAGR through 2032 due to its potential to provide targeted, effective treatments for these complex genetic disorders. Monoclonal antibodies offer a high degree of specificity, allowing them to bind to and neutralize specific proteins or cells involved in the pathogenesis of skeletal dysplasia. This precision can lead to improved therapeutic outcomes and reduced side effects compared to traditional treatments.

With respect to distribution channel, the skeletal dysplasia market from the hospital pharmacies segment will expand exponentially between 2024 and 2032 owing to their critical role in the administration and management of specialized treatments for rare conditions. Hospital pharmacies are equipped to handle complex as well as costly medications to provide tailored drug regimens for patients while ensuring proper dosing and monitoring.

Asia Pacific skeletal dysplasia industry is anticipated to grow at a notable pace over 2024-2032. The growth is attributed to the increasing awareness, improving healthcare infrastructure, and the rising investments in rare disease research. The expansion of healthcare facilities and the availability of specialized medical services in countries like China, India, and Japan are improving access to advanced therapies. Investments in R&D activities, often supported by government initiatives and private sector funding will also favor the regional market growth.

Table of Contents

Chapter 1 Methodology & Scope

• 1.1 Market scope & definitions
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Base estimates & calculations
  • 1.3.1 Base year calculation
  • 1.3.2 Key trends for market estimation
• 1.4 Forecast model
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
  • 1.5.2 Data mining sources

Chapter 2 Executive Summary

• 2.1 Industry 360° synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Increasing prevalence of skeletal dysplasia
    • 3.2.1.2 Increasing awareness and screening
    • 3.2.1.3 Rising healthcare expenditure
    • 3.2.1.4 Increasing geriatric population
  • 3.2.2 Industry pitfalls & challenges
    • 3.2.2.1 High cost of therapy
    • 3.2.2.2 Regulatory and reimbursement challenges
• 3.3 Growth potential analysis
• 3.4 Technological landscape
• 3.5 Regulatory landscape
• 3.6 Porter's analysis
• 3.7 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

• 4.1 Introduction
• 4.2 Company market share analysis
• 4.3 Competitive positioning matrix
• 4.4 Strategy outlook matrix

Chapter 5 Market Estimates and Forecast, By Dysplasia Type, 2021 - 2032 ($ Mn)

• 5.1 Key trends
• 5.2 Morquio A syndrome
• 5.3 X-linked hypophosphatemia
• 5.4 Hypophosphatasia
• 5.5 Achondroplasia
• 5.6 Fibrodysplasia ossificans progressive
• 5.7 Multiple osteochondromas
• 5.8 Other dysplasia types

Chapter 6 Market Estimates and Forecast, By Treatment, 2021 - 2032 ($ Mn)

• 6.1 Key trends
• 6.2 Enzyme replacement therapy
• 6.3 Human monoclonal antibody
• 6.4 Other treatments

Chapter 7 Market Estimates and Forecast, By Distribution Channel, 2021 - 2032 ($ Mn)

• 7.1 Key trends
• 7.2 Hospital pharmacies
• 7.3 Retail pharmacies
• 7.4 Online pharmacies

Chapter 8 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

• 8.1 Key trends
• 8.2 North America
  • 8.2.1 U.S.
  • 8.2.2 Canada
• 8.3 Europe
  • 8.3.1 Germany
  • 8.3.2 UK
  • 8.3.3 France
  • 8.3.4 Spain
  • 8.3.5 Italy
  • 8.3.6 Netherlands
  • 8.3.7 Rest of Europe
• 8.4 Asia Pacific
  • 8.4.1 Japan
  • 8.4.2 China
  • 8.4.3 India
  • 8.4.4 Australia
  • 8.4.5 South Korea
  • 8.4.6 Rest of Asia Pacific
• 8.5 Latin America
  • 8.5.1 Brazil
  • 8.5.2 Mexico
  • 8.5.3 Argentina
  • 8.5.4 Rest of Latin America
• 8.6 Middle East and Africa
  • 8.6.1 Saudi Arabia
  • 8.6.2 South Africa
  • 8.6.3 UAE
  • 8.6.4 Rest of Middle East and Africa

Chapter 9 Company Profiles

• 9.1 AbbVie Inc.
• 9.2 Alexion Pharmaceuticals, Inc.
• 9.3 Amgen Inc.
• 9.4 BioMarin Pharmaceutical Inc.
• 9.5 Horizon Therapeutics plc
• 9.6 Johnson & Johnson
• 9.7 Mallinckrodt Pharmaceuticals
• 9.8 Novartis AG
• 9.9 Pfizer Inc.
• 9.10 Regeneron Pharmaceuticals, Inc.
• 9.11 Sanofi
• 9.12 Sarepta Therapeutics, Inc.
• 9.13 Takeda Pharmaceutical Company Limited
• 9.14 Ultragenyx Pharmaceutical Inc.
• 9.15 Vertex Pharmaceuticals Incorporated